Efficacy and safety of simeprevir plus pegylated intereferon combination therapy for HCV genotype 1 patients with chronic renal failure

Efficacy and safety of simeprevir plus pegylated intereferon combination therapy for HCV genotype 1 patients with chronic renal failure - Simeprevir plus pegylated intereferon combination therapy for HCV genotype 1 patients with chronic renal failure

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012668

Enrollment

Registered

2013-12-25

Start date

2013-12-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic infection with hepatitis C virus

Interventions

Simeprevir plus Peg-IFN combination therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Hemodialysis patients 2) Patients with chronic infection with hepatitis C virus genotype 1 and more than 5 log IU/ml

Exclusion criteria

Exclusion criteria: 1) Patients with co-infection with hepatitis B virus or human immunodeficiency virus or alcoholic liver disorder or autoimmune hepatitis. 2) Patients with uncompensated cirrhosis or hepatic failure 3) Patients with multiple organ failure or immunological deficiency 4) Patients with severe depression or past history of psychiatric disorder 5) Patients in pregnancy or lactating or patients who expect to become pregnant

Design outcomes

Primary

Measure	Time frame
- Investigating sustained virological response rate (the rate of undetectable HCV RNA at end of treatment and at 24 weeks after completion of treatment) of Simeprevir plus Peg-IFN combination therapy in HCV genotype 1 patients with chronic renal failure. - Investigating the factors for sustained virological response.	—

Countries

Japan

Contacts

Public ContactNaoki Hiramatsu

Osaka University Graduate school of Medicine Gastroenterology and Hepatology

hiramatsu@gh.med.osaka-u.ac.jp06-6879-3621

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026